Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1992;85:288-297

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ord, J. M.
Right arrow Articles by Sobel, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ord, J. M.
Right arrow Articles by Sobel, B. E.

Circulation, Vol 85, 288-297, Copyright © 1992 by American Heart Association


ARTICLES

Imaging of thrombi with tissue-type plasminogen activator rendered enzymatically inactive and conjugated to a residualizing label

JM Ord, J Hasapes, A Daugherty, SR Thorpe, SR Bergmann and BE Sobel
Cardiovascular Division, Washington University School of Medicine, St. Louis, Mo.

BACKGROUND. Contemporary cardiovascular practice relies increasingly on thrombolysis as a therapeutic modality. Its optimal use requires prompt, noninvasive delineation of thrombotic occlusion in arterial beds and rapid detection of reocclusion after initially successful thrombolysis. METHODS AND RESULTS. We have been developing an approach to noninvasively image thrombi in which plasminogen-activating properties of tissue-type plasminogen activator (t-PA) are attenuated by treatment with D-Phe-L-Pro-L-Arg-chloromethyl ketone (PPACK) and have shown that the inactive t-PA avidly and promptly binds to clots in vitro. In the present study, we conjugated this material to a residualizing label, radioiodinated dilactitol tyramine (*I-DLT), and characterized the potential use of the inactivated, conjugated t-PA as a radiopharmaceutical for imaging thrombi in vivo. The approach developed requires not only avid binding of the tracer to thrombi but also rapid clearance from plasma and a lack of prompt release of radiolabeled degradation products from the liver. The rapid clearance of unaltered or PPACK-treated t-PA was not influenced by conjugation to *I-DLT, but the release of radioiodinated degradation products into plasma after injection of *I-DLT-conjugated t-PA was markedly less than release of degradation products of directly radioiodinated t-PA. When 131I-DLT-PPACK-t-PA was infused for 15 minutes intravenously after a bolus injection of 20% in dogs with coronary, pulmonary, or carotid artery thrombi, clearance was rapid. Mean +/- SEM thrombus-to-blood ratios of radioactivity were high, ranging from 37 +/- 9:1 and 2.8 +/- 0.6:1 with carotid thrombi formed concomitantly or approximately 30 minutes before infusion of tracer, respectively, to 35:1 for concomitantly formed coronary thrombi, 42 +/- 7:1 and 8.1 +/- 0.8:1 for concomitantly formed and preformed pulmonary thrombi, respectively, and 18:1 for a preformed femoral artery thrombus. Thrombi were detectable by planar gamma scintigraphy even though image quality was affected adversely by low concentrations of radioactivity that in aggregate composed a relatively large amount of radioactivity in underlying and overlying tissues. This limitation was overcome by tomographic imaging, which was used to detect both femoral and pulmonary thrombi. CONCLUSIONS. Use of enzymatically inactivated t-PA coupled to a residualizing label permits rapid detection and localization of thrombi in vivo.


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
D. R. Elmaleh, A. J. Fischman, A. Tawakol, A. Zhu, T. M. Shoup, U. Hoffmann, A.-L. Brownell, and P. C. Zamecnik
Detection of inflamed atherosclerotic lesions with diadenosine-5',5'''-P1,P4-tetraphosphate (Ap4A) and positron-emission tomography
PNAS, October 24, 2006; 103(43): 15992 - 15996.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Ohtsuki, M. Hayase, K. Akashi, S. Kopiwoda, and H. W. Strauss
Detection of Monocyte Chemoattractant Protein-1 Receptor Expression in Experimental Atherosclerotic Lesions: An Autoradiographic Study
Circulation, July 10, 2001; 104(2): 203 - 208.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. R. Elmaleh, J. Narula, J. W. Babich, A. Petrov, A. J. Fischman, B.-A. Khaw, E. Rapaport, and P. C. Zamecnik
Rapid noninvasive detection of experimental atherosclerotic lesions with novel 99mTc-labeled diadenosine tetraphosphates
PNAS, January 20, 1998; 95(2): 691 - 695.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. R. Stratton, T. A. Dewhurst, S. Kasina, J. M. Reno, M. D. Cerqueira, D. G. Baskin, and J. F. Tait
Selective Uptake of Radiolabeled Annexin V on Acute Porcine Left Atrial Thrombi
Circulation, November 15, 1995; 92(10): 3113 - 3121.
[Abstract] [Full Text]


Home page
CirculationHome page
V. H. D. Bruyn, S. R. Bergmann, B. A. Keyt, and B. E. Sobel
Visualization of Thrombi in Pulmonary Arteries With Radiolabeled, Enzymatically Inactivated Tissue-Type Plasminogen Activator
Circulation, September 1, 1995; 92(5): 1320 - 1325.
[Abstract] [Full Text]


Home page
CirculationHome page
J. Narula, A. Petrov, C. Bianchi, C. C. Ditlow, B. C. Lister, J. Dilley, I. Pieslak, F. W. Chen, V. P. Torchilin, and B.-A. Khaw
Noninvasive Localization of Experimental Atherosclerotic Lesions With Mouse/Human Chimeric Z2D3 F(ab')2 Specific for the Proliferating Smooth Muscle Cells of Human Atheroma : Imaging With Conventional and Negative Charge–Modified Antibody Fragments
Circulation, August 1, 1995; 92(3): 474 - 484.
[Abstract] [Full Text]